S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
DFTX · Definium Therapeutics, Inc. Common Shares
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Definium Therapeutics Inc (DFTX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$35.47
+0.38
(+1.07%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$35.47
$35.13
$36.31
52-WEEK RANGE
$35.47
$10.46
$49.70
What's happening
- DFTX is up 1.07% today, trading at $35.47. — Live quote
- Volume today (520,735) is well below its 3-month average of 2,715,520. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.44 actual vs. $-0.56 estimated (-158.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 14
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (24 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
DFTX
+146.23%
vs S&P 500
+133.83%
1-YEAR RETURN
DFTX
+141.54%
vs S&P 500
+126.17%
6-MONTH RETURN
DFTX
+48.85%
3-MONTH RETURN
DFTX
-22.97%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.44
Est. $-0.56
MISS -158.2%
2026-04-26 (Q1 2026)
$-0.71
Est. $-0.50
MISS -41.4%
2026-01-26 (Q4 2025)
$-0.50
Est. $-0.50
MISS -0.5%
2025-10-26 (Q3 2025)
$-0.78
Est. $-0.51
MISS -52.6%
Valuation Measures & Ratios
Enterprise Value4$4.11B
Forward P/E5—
PEG Ratio6-0.07
Price / Sales (TTM1)—
Price / Book76.38
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-85.23%
Return on Assets (ROA9)-64.58%
Avg Volume (3M)2,715,520
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $5.19B | $2.05B | $1.02B | $555.2M | $390.2M |
| P/E | -15.00 | -9.75 | -6.91 | -6.48 | -4.01 |
| Price/Book | 5.65 | 7.36 | 7.79 | 2.99 | 1.75 |
| ROE | -37.67% | -75.47% | -112.59% | -46.19% | -43.66% |
| ROA | -31.10% | -52.44% | -62.06% | -32.30% | -35.34% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short11,344,959
Change from Prior Settlement-3.74%
% of Float—
Days to Cover (Short Ratio)4.89
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +141.5%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on DFTX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$75.1M | -$59.2M | -$45.7M | -$40.9M | -$32.2M | -$24.8M | -$24.5M | -$22.2M |
| Net income | -$159.0M | -$77.1M | -$67.3M | -$42.7M | -$23.3M | -$13.7M | -$5.9M | -$54.4M |
| EPS (diluted) | $-1.44 | $-0.71 | $-0.78 | $-0.50 | $-0.35 | $-0.27 | $-0.26 | $-1.14 |
| EPS (basic) | $-1.44 | $-0.71 | $-0.78 | $-0.50 | $-0.27 | $-0.18 | $-0.08 | $-1.14 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.11B | $401.3M | $440.1M | $236.9M | $265.1M | $275.3M | $302.2M | $319.8M |
| Total liabilities | $194.2M | $122.4M | $107.8M | $106.3M | $79.7M | $52.5M | $60.7M | $57.6M |
| Stockholders' equity | $918.7M | $278.8M | $332.3M | $130.6M | $185.4M | $222.8M | $241.4M | $262.2M |
| Total current assets | $1.09B | $380.6M | $419.3M | $215.8M | $189.1M | $221.7M | $281.6M | $299.4M |
| Total current liabilities | $157.2M | $81.1M | $66.7M | $65.4M | $38.0M | $30.5M | $38.8M | $33.3M |
| Cash & equivalents | $655.3M | $262.5M | $257.8M | $20.0M | $33.4M | $82.9M | $273.7M | $295.3M |
| Marketable securities (current) | $428.6M | $110.9M | $153.8M | $189.1M | $149.6M | $129.6M | $0 | — |
| Marketable securities (non-current) | — | — | — | — | $54.9M | $33.1M | $0 | — |
| Goodwill | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M |
| Intangible assets | — | — | — | — | — | — | $0 | — |
| Other non-current assets | $880.0K | $812.0K | $862.0K | $1.1M | $1.2M | $606.0K | $613.0K | $493.0K |
| Accounts payable | $7.0M | $7.1M | $5.3M | $8.1M | $4.2M | $2.3M | $2.0M | $2.1M |
| Accrued liabilities | $37.2M | $24.5M | $20.4M | $19.0M | $14.8M | $11.5M | $12.8M | $8.8M |
| Long-term debt | $36.5M | $40.8M | $40.6M | $40.4M | $41.2M | $22.0M | $21.9M | $24.3M |
| Other non-current liabilities | $549.0K | $559.0K | $496.0K | $519.0K | $543.0K | — | — | — |
| Common stock & paid-in capital | — | — | — | — | — | — | $0 | $0 |
| Retained earnings | -$818.8M | -$659.8M | -$582.7M | -$532.2M | -$465.0M | -$422.2M | -$398.9M | -$364.1M |
| Accumulated other comprehensive income (loss) | $417.0K | $824.0K | $1.1M | $1.0M | $807.0K | $802.0K | $819.0K | $821.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$52.8M | -$42.6M | -$43.0M | -$29.6M | -$29.6M | -$29.4M | -$25.4M | -$17.2M |
| Investing cash flow | -$316.7M | $42.0M | $35.0M | $15.4M | -$39.5M | -$162.5M | $0 | $0 |
| Financing cash flow | $762.3M | $5.3M | $245.9M | $749.0K | $19.6M | $1.0M | $3.8M | $69.4M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$162.0K | $1.8M | -$2.8M | $3.9M | $1.9M | $258.0K | -$139.0K | -$534.0K |
| Purchases of investments | $355.7M | $0 | $6.0M | $26.6M | $73.3M | $162.5M | $0 | $0 |
| Sales/maturities of investments | $39.0M | $42.0M | $41.0M | $42.0M | $33.8M | $0 | $0 | $0 |
| Other investing activities | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$166.3M | -$103.9M | -$93.9M | -$66.3M | -$93.9M |
| Net income | -$183.8M | -$108.7M | -$95.7M | -$56.8M | -$93.0M |
| EPS (diluted) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
| EPS (basic) | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M |
| Total liabilities | $107.8M | $60.7M | $46.4M | $19.1M | $12.3M |
| Stockholders' equity | $332.3M | $241.4M | $78.1M | $150.9M | $151.7M |
| Total current assets | $419.3M | $281.6M | $103.9M | $146.1M | $137.2M |
| Total current liabilities | $66.7M | $38.8M | $32.2M | $17.9M | $10.4M |
| Cash & equivalents | $257.8M | $273.7M | $99.7M | $142.1M | $133.5M |
| Marketable securities (current) | $153.8M | $0 | — | — | — |
| Goodwill | $19.9M | $19.9M | $19.9M | $19.9M | $19.9M |
| Intangible assets | — | $0 | $527.0K | $3.7M | $6.9M |
| Other non-current assets | $862.0K | $613.0K | $224.0K | $331.0K | — |
| Accounts payable | $5.3M | $2.0M | $4.1M | $2.1M | $4.2M |
| Accrued liabilities | $20.4M | $12.8M | $11.6M | $5.9M | $6.2M |
| Long-term debt | $40.6M | $21.9M | $14.1M | — | — |
| Other non-current liabilities | $496.0K | — | $32.0K | $1.2M | $1.9M |
| Common stock & paid-in capital | — | $0 | $0 | — | — |
| Retained earnings | -$582.7M | -$398.9M | -$290.2M | -$194.5M | -$137.7M |
| Accumulated other comprehensive income (loss) | $1.1M | $819.0K | $343.0K | $627.0K | $1.0M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$131.6M | -$79.1M | -$64.4M | -$50.1M | -$45.8M |
| Investing cash flow | -$151.6M | $0 | — | — | -$297.0K |
| Financing cash flow | $267.3M | $253.2M | $21.8M | $59.1M | $98.8M |
| Deferred income taxes | — | — | — | — | -$1.2M |
| Change in accounts payable | $3.3M | -$2.1M | $2.0M | -$2.1M | $1.3M |
| Purchases of investments | $268.4M | $0 | — | — | — |
| Sales/maturities of investments | $116.8M | $0 | — | — | — |
| Tax withholding on stock comp | $0 | $54.0K | $0 | $407.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding DFTX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers79.6%
Shares Outstanding110,684,720
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11,232,834 | $528.4M | 10.15% | +32.5% | 2026-08-07 |
| Avoro Capital Advisors LLC | 7,188,888 | $338.2M | 6.49% | +43.8% | 2026-08-14 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 6,845,276 | $322.0M | 6.18% | +15.8% | 2026-08-14 |
| Jupiter Topco LLC | 5,615,645 | $264.0M | 5.07% | +0.0% | 2026-08-14 |
| Capital World Investors | 5,367,723 | $252.5M | 4.85% | +0.0% | 2026-08-07 |
| FMR LLC | 4,752,921 | $223.6M | 4.29% | +162.6% | 2026-08-13 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4,652,032 | $218.8K | 4.20% | +6545.7% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,644,813 | $171.5M | 3.29% | +46.1% | 2026-08-12 |
| State Street Corp | 3,065,390 | $144.2M | 2.77% | +24.0% | 2026-08-07 |
| Capital International Investors | 2,963,410 | $139.4M | 2.68% | +0.0% | 2026-08-07 |
| Octagon Capital Advisors LP | 2,950,000 | $138.8M | 2.67% | +20.9% | 2026-08-14 |
| WELLINGTON MANAGEMENT GROUP LLP | 2,949,734 | $138.8M | 2.66% | +126.1% | 2026-08-14 |
| Deep Track Capital, LP | 2,750,000 | $129.4M | 2.48% | -8.3% | 2026-08-14 |
| Commodore Capital LP | 2,000,000 | $94.1M | 1.81% | +0.0% | 2026-08-14 |
| ALLIANCEBERNSTEIN L.P. | 1,803,287 | $34.1M | 1.63% | +1866.4% | 2026-08-14 |
| Goldman Sachs Group Inc | 1,800,852 | $84.7M | 1.63% | +7.5% | 2026-08-14 |
| CITADEL ADVISORS LLC | 1,688,587 | $79.4M | 1.53% | +26.6% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,648,426 | $77.5M | 1.49% | +88.9% | 2026-06-30 |
| RA CAPITAL MANAGEMENT, L.P. | 1,500,000 | $70.6M | 1.36% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,486,454 | $69.9M | 1.34% | +35.5% | 2026-06-30 |
| Siren, L.L.C. | 1,419,493 | $66.8M | 1.28% | +54.4% | 2026-08-13 |
| MARSHALL WACE, LLP | 1,298,946 | $61.1M | 1.17% | +8.2% | 2026-08-13 |
| Northern Trust Corp | 1,169,238 | $55.0M | 1.06% | +46.3% | 2026-08-12 |
| Ameriprise Financial Inc | 1,148,363 | $54.0M | 1.04% | +18.8% | 2026-08-14 |
| Nuveen, LLC | 1,105,314 | $52.0M | 1.00% | +58.3% | 2026-08-11 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-22 to 2026-09-25
Recent transactions
- Insiders have net sold 140,082 shares over the last 182 days, across 0 purchases and 11 sales.
- Most recent: Karlin Daniel (Chief Medical Officer) — Open market sale of 10,853 shares on 2026-09-25.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)140,082 sh(11 txns)
Net Shares-140,082
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Karlin Daniel | Chief Medical Officer | Open market sale | 2026-09-25 | 10,853 |
| Barrow Robert | Chief Executive Officer | Open market sale | 2026-09-25 | 31,550 |
| Wiley Matthew T. | Chief Commercial Officer | Open market sale | 2026-09-25 | 3,097 |
| Sullivan Mark | Chief Legal Officer | Open market sale | 2026-09-25 | 14,051 |
| Roberts Brandi | Chief Financial Officer | Open market sale | 2026-09-25 | 3,377 |
| Vallone Carol A | Reporting person | Option exercise | 2026-09-18 | 1,086 |
| Krebs Andreas | Reporting person | Option exercise | 2026-09-18 | 1,629 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-25 | Karlin Daniel | Chief Medical Officer | Open market sale | 10,853 | $36.57 |
| 2026-09-25 | Barrow Robert | Chief Executive Officer | Open market sale | 31,550 | $36.57 |
| 2026-09-25 | Wiley Matthew T. | Chief Commercial Officer | Open market sale | 3,097 | $36.57 |
| 2026-09-25 | Sullivan Mark | Chief Legal Officer | Open market sale | 14,051 | $36.57 |
| 2026-09-25 | Roberts Brandi | Chief Financial Officer | Open market sale | 3,377 | $36.57 |
| 2026-09-18 | Vallone Carol A | Reporting person | Option exercise | 1,086 | $35.52 |
| 2026-09-18 | Krebs Andreas | Reporting person | Option exercise | 1,629 | $35.52 |
| 2026-09-14 | Karlin Daniel | Chief Medical Officer | Grant / award | 200,000 | $0.00 |
| 2026-09-14 | Wiley Matthew T. | Chief Commercial Officer | Grant / award | 125,000 | $0.00 |
| 2026-09-14 | Sullivan Mark | Chief Legal Officer | Grant / award | 125,000 | $0.00 |
| 2026-09-14 | Roberts Brandi | Chief Financial Officer | Grant / award | 125,000 | $0.00 |
| 2026-09-14 | Barrow Robert | Chief Executive Officer | Grant / award | 750,000 | $0.00 |
| 2026-09-03 | Barrow Robert | Chief Executive Officer | Open market sale | 19,023 | $37.94 |
| 2026-09-02 | Barrow Robert | Chief Executive Officer | Grant / award | 40,000 | $0.00 |
| 2026-08-12 | Barrow Robert | Chief Executive Officer | Grant / award | 375,000 | $0.00 |
| 2026-08-12 | Karlin Daniel | Chief Medical Officer | Grant / award | 100,000 | $0.00 |
| 2026-08-12 | Sullivan Mark | Chief Legal Officer | Grant / award | 62,500 | $0.00 |
| 2026-08-12 | Wiley Matthew T. | Chief Commercial Officer | Grant / award | 62,500 | $0.00 |
| 2026-08-12 | Roberts Brandi | Chief Financial Officer | Grant / award | 62,500 | $0.00 |
| 2026-06-25 | Sullivan Mark | Chief Legal Officer | Open market sale | 13,008 | $45.03 |
| 2026-06-25 | Roberts Brandi | Chief Financial Officer | Open market sale | 3,013 | $45.03 |
| 2026-06-25 | Barrow Robert | Chief Executive Officer | Open market sale | 29,208 | $45.03 |
| 2026-06-25 | Karlin Daniel | Chief Medical Officer | Open market sale | 10,035 | $45.03 |
| 2026-06-25 | Wiley Matthew T. | Chief Commercial Officer | Open market sale | 2,867 | $45.03 |
| 2026-06-22 | Wiley Matthew T. | Chief Commercial Officer | Grant / award | 62,500 | $0.00 |
| 2026-06-22 | Barrow Robert | Chief Executive Officer | Grant / award | 375,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 01:25 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-29 | 4 | 2026-09-25 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-18 | 4 | 2026-09-18 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-14 | 4 | 2026-09-14 | View on SEC.gov → |
Recent news
Headlines about DFTX (Definium Therapeutics, Inc. Common Shares). Links open the publisher — we don’t host full articles.
-
DFTX Nov 2026 25.000 call (DFTX261120C00025000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
DFTX Nov 2026 37.000 call (DFTX261120C00037000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Yahoo Finance · 2026-10-19 -
(DFTX) Risk Channels and Responsive Allocation
Stock Traders Daily · 2026-10-18 -
DFTX Nov 2026 30.000 call (DFTX261120C00030000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-17 -
DFTX Jan 2027 33.000 put (DFTX270115P00033000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-16 -
DFTX Nov 2026 37.000 put (DFTX261120P00037000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-15 -
DFTX Nov 2026 37.000 put (DFTX261120P00037000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-15
No headlines in this category right now — try “All”.